VANCOUVER, British Columbia, July 14, 2005 (PRIMEZONE) -- ProtoKinetix, Inc. (OTCBB:PKTX) announces a major collaborative agreement with one of the world's most prestigious blood specialty institutions. The Etablissment Francais du Sang-Alsace (EFS), which is affiliated with the Louis Pasteur University in Strasbourg, provides the premier research facilities in the field of hematology. EFS will be deploying their considerable physical and intellectual resources to the testing of synthesized AFGP characteristics as they apply to the preservation of blood products. With extensive world wide operations in Europe, Asia, Africa, and South America, EFS is in a unique position to identify the vital role that synthetic AFGP can play in the storage and transportation of blood products throughout the world.
About ProtoKinetix:
ProtoKinetix, Inc. is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors,
Dr. John Todd, President